AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
30 nov. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Patient screening and dosing ongoing in Turkey and HungaryTopline data expected in Q2 2021 for the Combination Trial DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....
AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients
17 nov. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Potential to add additional study arm utilizing immediate release capsules Trial objectives, endpoints and statistical analysis to remain the same DELRAY BEACH, Fla., Nov. 17, 2020 (GLOBE...
AzurRx BioPharma Announces Formation of Scientific Advisory Board
21 oct. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Globally recognized experts in cystic fibrosis and chronic pancreatitis care and research to support AzurRx in advancing the clinical development of MS1819 NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE)...
AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis
14 oct. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Two clinical trial sites activated in Turkey, with patient screening initiatedFollows activation of six clinical sites in Hungary and dosing of first eight patientsTopline data expected in Q2 2021 ...
AzurRx BioPharma CEO Issues Letter to Shareholders
07 oct. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
31 août 2020 08h00 HE
|
AzurRx BioPharma, Inc.
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
17 août 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Three clinical trial sites activated in Poland, with patient screening initiatedFollows activation of six clinical sites in the U.S. and dosing of first three patientsTopline data expected in Q1 2021 ...
AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
13 août 2020 08h00 HE
|
AzurRx BioPharma, Inc.
First three patients enrolled in dose escalation trial using delayed-release enteric capsulesTopline data expected in 1H 2021 NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....
AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product
07 mai 2020 08h00 HE
|
AzurRx BioPharma, Inc.
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)
05 mai 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Received ~$2.52 million in aggregate CIR payments in 2020CIR to be used to fund on-going MS1819 Phase 2 clinical studies in Europe NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma,...